190 related articles for article (PubMed ID: 9569463)
1. Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products.
Pride MW; Bailey CR; Muchmore E; Thanavala Y
Vaccine; 1998 Apr; 16(6):543-50. PubMed ID: 9569463
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice.
Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
J Viral Hepat; 1998 Nov; 5 Suppl 2():5-8. PubMed ID: 9857353
[TBL] [Abstract][Full Text] [Related]
3. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice.
Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
Vaccine; 1999 Jun; 17(20-21):2528-37. PubMed ID: 10418899
[TBL] [Abstract][Full Text] [Related]
4. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
[TBL] [Abstract][Full Text] [Related]
6. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
7. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
Raz R; Koren R; Bass D
Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
[TBL] [Abstract][Full Text] [Related]
9. A novel, recombinant triple antigen hepatitis B vaccine (Hepacare).
Page M; Jones CD; Bailey C
Intervirology; 2001; 44(2-3):88-97. PubMed ID: 11509870
[TBL] [Abstract][Full Text] [Related]
10. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
Kuroda S; Fujisawa Y; Iino S; Akahane Y; Suzuki H
Vaccine; 1991 Mar; 9(3):163-9. PubMed ID: 1828318
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients.
Ilan Y; Nagler A; Zeira E; Adler R; Slavin S; Shouval D
Bone Marrow Transplant; 2000 Sep; 26(6):633-8. PubMed ID: 11035369
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D; Roggendorf H; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
[TBL] [Abstract][Full Text] [Related]
13. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
[TBL] [Abstract][Full Text] [Related]
14. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer.
Emir S; Büyükpamuk M; Akyüz C; Kutluk T; Güler E; Cağlar K
Pediatr Hematol Oncol; 2002 Jun; 19(4):227-33. PubMed ID: 12051588
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection.
Böcher WO; Herzog-Hauff S; Herr W; Heermann K; Gerken G; Meyer Zum Büschenfelde KH; Löhr HF
Clin Exp Immunol; 1996 Jul; 105(1):52-8. PubMed ID: 8697635
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
[TBL] [Abstract][Full Text] [Related]
18. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines.
Leroux-Roels G; Van Hecke E; Michielsen W; Voet P; Hauser P; Pêtre J
Vaccine; 1994 Jul; 12(9):812-8. PubMed ID: 7975860
[TBL] [Abstract][Full Text] [Related]
19. Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions.
Steward MW; Sisley BM; Stanley C; Brown SE; Howard CR
Clin Exp Immunol; 1988 Jan; 71(1):19-25. PubMed ID: 3349646
[TBL] [Abstract][Full Text] [Related]
20. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
